BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9725045)

  • 1. [Radiotherapy combined with daily administration of low-dose cisplatin for squamous cell carcinomas of the head and neck].
    Hato N; Yumoto E; Hyodo M; Hinohira Y; Kawamura T; Fujii T
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1533-7. PubMed ID: 9725045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Radiotherapy combined with daily administration of low dose cisplatin for head and neck cancer].
    Hinohira Y; Yumoto E; Takahashi H; Mori T; Kawamura T; Takechi T
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):561-5. PubMed ID: 8678513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck.
    Jeremic B; Milicic B; Dagovic A; Vaskovic Z; Tadic L
    J Clin Oncol; 2004 Sep; 22(17):3540-8. PubMed ID: 15337803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Non-randomized study on the effects of preoperative radiotherapy and daily administration of low-dose cisplatin against those of radiotherapy alone for oral cancer--effects on local control, control of metastases, and overall survival].
    Kurita H; Ohtsuka A; Kobayashi H; Kurashina K; Shikama N; Oguchi M
    Gan To Kagaku Ryoho; 2000 Jan; 27(1):59-64. PubMed ID: 10660734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility study of single agent Cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results.
    Zenda S; Onozawa Y; Tahara M; Kawashima M; Shikama N; Sasaki S; Boku N
    Jpn J Clin Oncol; 2007 Oct; 37(10):725-9. PubMed ID: 17925299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Katori H; Tsukuda M; Taguchi T
    Cancer Chemother Pharmacol; 2007 May; 59(6):789-94. PubMed ID: 17053926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck.
    Uygun K; Bilici A; Karagol H; Caloglu M; Cicin I; Aksu G; Fayda M; Uzunoglu S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):601-5. PubMed ID: 19123002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
    Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A combination of low-dose carboplatin (CBDCA) and radiation therapy in head and neck cancer patients--response and hematologenic toxicity].
    Watanabe N; Kaneko T; Fujitani S; Umeyama M; Nomura Y; Zusho H; Yamada Y; Nanba G; Asahina N; Sugio Y; Okamoto Y; Daida T; Tokumaru T
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):101-6. PubMed ID: 9987505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
    Choi YJ; Chung JS; Shin HJ; Cho GJ; Wang SG; Lee BJ; Cho BM; Joo YD; Sohn CH
    J Laryngol Otol; 2008 Aug; 122(8):848-53. PubMed ID: 18047761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma.
    Nuyts S; Dirix P; Clement PM; Poorten VV; Delaere P; Schoenaers J; Hermans R; Van den Bogaert W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1088-95. PubMed ID: 18707823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615.
    Robbins KT; Kumar P; Harris J; McCulloch T; Cmelak A; Sofferman R; Levine P; Weisman R; Wilson W; Weymuller E; Fu K
    J Clin Oncol; 2005 Mar; 23(7):1447-54. PubMed ID: 15735120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.
    Huguenin P; Beer KT; Allal A; Rufibach K; Friedli C; Davis JB; Pestalozzi B; Schmid S; Thöni A; Ozsahin M; Bernier J; Töpfer M; Kann R; Meier UR; Thum P; Bieri S; Notter M; Lombriser N; Glanzmann C
    J Clin Oncol; 2004 Dec; 22(23):4665-73. PubMed ID: 15534360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Katori H; Tsukuda M; Watai K
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
    Kohno N; Kitahara S; Tamura E; Tanabe T; Nakanoboh M; Kawada M; Shirasaka T
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():592-9. PubMed ID: 10895216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
    Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
    Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
    Ang KK; Harris J; Garden AS; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS
    J Clin Oncol; 2005 May; 23(13):3008-15. PubMed ID: 15860857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.